Business Context and Reporting Period
Company: Pharming Group N.V.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: April 16, 2026
Context: The filing announces the convening of the 2026 Annual General Meeting of Shareholders (AGM) scheduled for May 28, 2026. Pharming Group is a global biopharmaceutical company developing medicines for rare and life-threatening diseases.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance announcement rather than a financial results report.
Material Changes
No material financial changes or operational updates versus prior periods are disclosed in this filing.
Guidance, Outlook, and Corporate Actions
AGM Agenda Items:
- Auditor Appointment: Proposal to appoint KPMG N.V. as external auditor for the financial years 2026 through 2028.
- Remuneration Policy: Proposal to amend the Remuneration policy for the Board of Directors regarding fees for Non-Executive Directors.
- Share Capital: Renewal of authorizations for the Board to issue shares (including rights to acquire shares) and to repurchase shares.
Meeting Details: The AGM will be held at the Corpus Congress Centre in Oegstgeest, the Netherlands, and will be webcast live.
Investor Verification Checklist
- Verify the final outcome of the auditor appointment (KPMG N.V.) at the May 28, 2026 AGM.
- Review the specific amendments to the Non-Executive Director remuneration policy.
- Confirm the scope and limits of the renewed share issuance and repurchase authorizations.
- Check the Company's website for the full Notice to Convene and Proxy materials.